Category Archives: Immunotherapy

June is Cancer Immunotherapy Month

June is Cancer Immunotherapy Awareness Month
June is Cancer Immunotherapy Awareness Month

In the fight against cancer, immunotherapy has been a game-changer. The Society of Immunotherapy for Cancer (SITC) is recognizing June as Cancer Immunotherapy Month to recognize and promote the value of these treatments.

Putting Immunotherapy in the Public Eye

The SITC observes Cancer Immunotherapy Month by promoting public awareness of immunotherapy and sponsoring educational events for both healthcare professionals and patients.

Here are a few of the programs scheduled for the upcoming month:

• “Cancer Immunity and Immunotherapy” is being held as part of the annual meeting of the Federation of Clinical Immunology Societies. Presentations will focus on tumor immunology and therapies such as vaccines, CAR-T cells and checkpoint inhibitors.

• “Incorporating Radiation Oncology into Immunotherapy” is a two-day workshop exploring the challenges and opportunities of combining the different methods into one integrative treatment.

• “Rational Combinations 360º” is a comprehensive examination of combining therapies as it relates to business, clinical and scientific aspects.

How Can You Participate?

Everyone has been touched by cancer in one way or another. There are a number of ways you can support Cancer Immunotherapy Month.

• Join the Cancer Immunotherapy CONNECT Open Forum and share your stories with other members.

• Purchase a SITC Cure t-shirt.

• Post your support of immunotherapy for cancer research on Twitter, Facebook and other social media platforms.

• Donate to the Forward Fund for immunotherapy research.

State-of-the-Art Immunotherapy for Cancer at Issels®

Our founder, Dr. Josef M. Issels, was a pioneer in the development and use of immunotherapy. Visit our website for more information about Dr. Issels and our individually tailored non-toxic immunotherapy programs.

Cancer Risk May Be Identified by the Oral Microbiome

Hold On, You're Telling Me the Bacteria in My Mouth Can Tell What Type of Cancer I Might Have?
Hold On, You’re Telling Me the Bacteria in My Mouth Can Tell What Type of Cancer I Might Have?

For years, the medical community has been telling us that proper oral hygiene is crucial for maintaining good overall health. Scientists are now finding that bacteria in your mouth may actually reveal your risk for different types of cancer.

What Does the Oral Microbiome Tell Us?

Here are some of the major links researchers have uncovered between mouth bacteria and cancer:

• Fusobacterium, which causes bleeding gums, is hundreds of times more prevalent in cancerous cells than in normal cells. This bacteria can trigger colon cancer as well as accelerate growth in any existing colon tumors.

• A study last year discovered the presence of P gingivalis, a bacteria that causes periodontal disease, in 61 percent of patients with esophageal cancer. Researchers also found that people with P gingivalis have a 60 percent higher risk of developing pancreatic cancer.

• Researchers at the University of Buffalo conducted a study in 2015 involving more than 73,000 postmenopausal women. Results showed that women with gum disease were 14 percent more likely to develop breast cancer.

What’s Next?

While conclusions have not been finalized, scientists suspect that the connection occurs when the bloodstream carries bacteria from the mouth to other organs. It’s hoped that further research will enable doctors to determine cancer risk simply by the type of bacteria present in the body.

Personally Tailored Cancer Treatment Based on Your Particular Needs

All cancer cases are different, so why should all cancer treatment be the same? Visit our website to learn why Issels® is the industry leader in state-of-the-art immunotherapy methods such as cancer vaccines and NK cells that are designed for your specific situation.

Could This Bacterial Molecule Stimulate the Immune System to Fight Cancer?

Get The Treatment You Need with Us!
Get The Treatment You Need with Us!

There’s a popular saying that goes, “Everything old is new again.” This may also hold true with immunotherapy for cancer, as researchers explore the possibility of enlisting your body’s ancient defenses against bacterial threats to fight tumors.

Going Back to the Future

A team at Fred Hutchinson Cancer Research Center in Seattle recently conducted a trial of an experimental drug on 15 patients with advanced sarcoma. The drug, known as G100, was based on a molecule called lipopolysaccharide that is carried within certain bacteria.

Lipopolysaccharide is unique to these organisms, so its presence has historically triggered a prompt and powerful inflammatory response. According to scientists, the pathway to this response dates back so far in the evolutionary cycle that it’s nearly identical in all animals.

Over a period of two to three months, participants received an injection of G100 directly into the tumor, along with a course of focused radiation. The injected tumors stopped growing, shrank or even disappeared in 14 of the 15 patients, while tumor growth throughout the body stopped in six of them.

Boosting the Body’s Immune System

Researchers are theorizing that the drug makes the tumor “hot” in terms of activating an immune response aimed specifically at the cancer cells. The next step involves combining G100 injections with an as-yet-undecided immunotherapy agent to see if the treatment can boost the cancer-fighting immune response throughout the body.

Using State-of-the-Art Methods to Fight Cancer

At Issels®, we stay up-to-date on all the latest advancements in immunotherapy for cancer. Contact us to learn more about our non-toxic, integrative treatment programs that are specifically designed for your individual needs.

The Cost of Some New Cancer Drugs Spiral Out of Reach for Some Patients

The Cost of Some Medications Is Rising
The Cost of Some Medications Is Rising

The last few years have brought exciting advances in immunotherapy for cancer, but innovation has come at a price … literally. Skyrocketing costs for cancer drugs are making them inaccessible for many who would benefit the most.

Cancer Drugs: The Price of Success

During the 10-year period between 2005 and 2015, Big Pharma’s pipeline of cancer drugs increased by 63 percent, with several reaching the market. As a result, the global market is projected to grow from $16.9 billion in 2015 to an astounding $75.8 billion in 2022.

But while competition generally serves to drive prices down, that’s not happening with the new cancer drugs. Factors such as market exclusivity, insurance plan structures and lack of head-to-head comparison studies combine to keep prices high.

One example is checkpoint inhibitors, which release the systemic “brakes” preventing the immune system from recognizing and attacking cancer cells. Bristol, Merck, Roche and Pfizer all have checkpoint inhibitors on the market, but each has an annual price tag approaching $150,000.

What’s the Answer?

Experts see no evidence that pharmaceutical companies, driven by the current free rein on pricing, are exploring more cost-effective solutions. President Donald Trump and lawmakers from both parties are prioritizing a search for methods to restrain spiraling cancer drug costs, ranging from more price negotiation to faster approval.

Issels® Leads the Field in Immunotherapy for Cancer

While the medical community and lawmakers grapple with the finances of immunotherapy for cancer, we have been successfully treating patients with individually developed non-toxic protocols for years. Contact us today to learn more about cancer vaccines, NK cells and other immunotherapy programs at Issels®.

Could Where You Live in Your Time Zone Affect Your Cancer Risk?

Does Your Time Zone Impact Cancer?
Tired When You Get Up? Could Your Time Zone Impact Cancer?

While the hour may be the same throughout a time zone, the degrees of sunlight and darkness are not. A recent study suggests that this quirk of nature may be linked to an increased cancer risk.

When Day Becomes Night

A research team at the National Cancer Institute was inspired by previous research showing slightly higher cancer risk among people who work the night shift. This finding was attributed to circadian disruption, which is a change in the body’s biological clock.

Shift workers experience extreme circadian disruption owing to almost complete reversal of day and night. The NCI researchers set out to see if the increased risk of cancer applied to minor disruptions in the body’s natural rhythms, referred to as social jet lag.

The most common example of social jet lag is rising at different times on work days and weekends, but the phenomenon also occurs with people living on either end of a time zone, where light and dark come at different times.

Effects of Social Jet Lag on Cancer Risk

After reviewing data from 4 million white adults who had been diagnosed with cancer, the NCI team found each five degrees of longitude toward the west resulted in an increased risk of three percent for men and four percent for women. Greater risk was also found specifically for breast cancer, prostate cancer and uterine cancer.

Issels®: Leading the Way in Immunotherapy for Cancer

Our Issels® clinic has been in the forefront of state-of-the-art immunotherapy for cancer treatments. Contact us to learn more about our personally tailored integrative programs.

Transformative Impact of Immunotherapy Tops Cancer News

Diverse Hands Holding The Word Cancer
Immunotherapy brings breakthroughs to cancer treatment.

For decades, cancer has been the main focus of innumerable medical researchers. During 2016, immunotherapy for cancer was designated the top advance in the field for the second consecutive year.

The Rapid Rise of Immunotherapy Treatment

The announcement was made in Clinical Cancer Advances 2017, the 12th annual report from the American Society of Clinical Oncology (ASCO). Dr. Daniel F. Hayes, president of ASCO, presented the report to Congress during a recent meeting to request continued funding for cancer research.

According to Dr. Hayes, immunotherapy was a “promising theoretical treatment” less than 10 years ago. In a relatively short span of time, it has become a “standard of care” that has positively affected thousands of patients.

“Immunotherapy 2.0”

Just how much progress has been made in immunotherapy for cancer? Since 2011, a total of 15 immune-targeted therapies have been approved. That success combined with continued improvements in identifying candidates and overcoming resistance mechanisms, led ASCO to dub it “Immunotherapy 2.0.”

Dr. Hayes also stressed the importance of federal funding in maintaining the momentum in cancer research. One prominent development that has made a significant impact is the Cancer Moonshot program. Former Vice President Joe Biden took up the cause after his son Beau’s death from brain cancer.

Issels®: Ahead of the Curve

While the rest of the medical community is embracing the value of immunotherapy for cancer, we have been in the forefront of successfully treating patients by boosting their own immune systems. Visit our website to learn more about cancer vaccines, NK cells and our other non-toxic, individually tailored programs.